- Supported exchanges /
- XETRA /
- NP5.XETRA
NEWRON PHARMACEUT. EO-20 (NP5 XETRA) stock market data APIs
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
NEWRON PHARMACEUT. EO-20 Financial Data Overview
| 8.55 | |
| 7.81 | |
| - | |
| 8.73 | |
| 8.27 | |
| 4.26-12 | |
| 157 M | |
| 19 232 K | |
| 9 057 K | |
| 0.701 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
NEWRON PHARMACEUT. EO-20 Fundamental Data is available in our Financial Data APIs
- Net Revenue 9 057 K
- EBITDA -11 492 000
- Earnings Per Share -0.91
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get NEWRON PHARMACEUT. EO-20 Earnings via APIs
- Latest Release 2024-09-19
- EPS/Forecast NaN
Get NEWRON PHARMACEUT. EO-20 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
